Atlas Trials

Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)

Clinical trial NCT06823401 · RECRUITING

Trial details

NCT number
NCT06823401
Sponsor
Fondazione Ricerca Traslazionale
Status
RECRUITING
Study type
OBSERVATIONAL
NSCLC
Start date
2021-05-20
Primary completion
2027-09-10
Enrollment
270

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.